论文部分内容阅读
目的观察吉西他滨单药周剂量治疗老年晚期非小细胞肺癌的疗效和不良反应。方法对45例老年晚期非小细胞肺癌患者(年龄≥65岁)应用吉西他滨800~1000 mg/m2,第1、8天,3~4周为1个周期,至少治疗2个周期评价疗效和不良反应。结果全组总有效率为26.7%(12/45),临床受益率为71.1%(32/45),无疾病进展生存时间为4.2个月,中位生存时间为8.3个月,1年生存率为31.1%(14/45),主要不良反应为骨髓抑制、胃肠道反应、皮疹和肝肾功能受损。结论吉西他滨单药周剂量治疗老年晚期非小细胞肺癌耐受性较好,生活质量较高。
Objective To observe the efficacy and side effects of gemcitabine monotherapy weekly in the treatment of elderly patients with advanced non-small cell lung cancer. Methods Forty-five elderly patients with advanced NSCLC (age≥65 years) received gemcitabine 800 ~ 1000 mg / m 2 for 1, 8 days and 3 to 4 weeks for at least 2 cycles to evaluate the efficacy and adverse effects reaction. Results The total effective rate was 26.7% (12/45) in the whole group, the clinical benefit rate was 71.1% (32/45), the progression-free survival time was 4.2 months, the median survival time was 8.3 months, and the 1-year survival rate Was 31.1% (14/45). The main adverse reactions were myelosuppression, gastrointestinal reactions, skin rashes and impaired liver and kidney function. Conclusion Gemcitabine monotherapy with weekly dose is better tolerated in elderly patients with advanced non-small cell lung cancer and higher quality of life.